PL2398468T3 - Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania - Google Patents

Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania

Info

Publication number
PL2398468T3
PL2398468T3 PL10704517T PL10704517T PL2398468T3 PL 2398468 T3 PL2398468 T3 PL 2398468T3 PL 10704517 T PL10704517 T PL 10704517T PL 10704517 T PL10704517 T PL 10704517T PL 2398468 T3 PL2398468 T3 PL 2398468T3
Authority
PL
Poland
Prior art keywords
processes
preparation
pharmaceutically acceptable
pharmaceutical compositions
acid addition
Prior art date
Application number
PL10704517T
Other languages
English (en)
Inventor
Simon Kukec
Mitja Stukelj
Franc Vrecer
Sabina Trost
Klavdija Meznar
Alen Kljajic
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42104454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2398468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of PL2398468T3 publication Critical patent/PL2398468T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL10704517T 2009-02-17 2010-02-17 Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania PL2398468T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SI200900040 2009-02-17
SI200900155 2009-06-02
SI200900186 2009-07-09
SI200900194 2009-07-15
SI200900309 2009-10-20
SI200900396 2009-12-28
SI201000006 2010-01-14
EP10704517.1A EP2398468B1 (en) 2009-02-17 2010-02-17 Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation

Publications (1)

Publication Number Publication Date
PL2398468T3 true PL2398468T3 (pl) 2017-06-30

Family

ID=42104454

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10704517T PL2398468T3 (pl) 2009-02-17 2010-02-17 Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania

Country Status (5)

Country Link
EP (1) EP2398468B1 (pl)
EA (1) EA024980B1 (pl)
PL (1) PL2398468T3 (pl)
SI (1) SI2398468T1 (pl)
WO (1) WO2010094471A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2398468T3 (pl) 2009-02-17 2017-06-30 Krka, D.D., Novo Mesto Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania
DE102009036646A1 (de) * 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
KR20140110096A (ko) 2010-04-08 2014-09-16 테바 파마슈티컬 인더스트리즈 리미티드 프라수그렐 염의 결정형
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
TR201005900A1 (tr) * 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
US10004682B2 (en) 2010-08-24 2018-06-26 Rutgers, The State University Of New Jersey Formulation and manufacture of pharmaceuticals by impregnation onto porous carriers
TWI557130B (zh) * 2011-04-25 2016-11-11 孫遠 提高藥物溶出度的組成物及其製備方法
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060560A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
EP2722037A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Prasugrel formulations
CN103893137B (zh) * 2012-12-27 2017-09-29 上海创诺制药有限公司 一种制备普拉格雷片剂的方法
CN104173316B (zh) * 2013-05-22 2018-05-18 山东新时代药业有限公司 一种氢溴酸普拉格雷的胶囊剂
EP2979693A1 (en) * 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) * 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3156049A1 (en) * 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmaceutical composition of prasugrel
GR1009230B (el) * 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη
WO2018073437A1 (en) 2016-10-21 2018-04-26 Laboratorios Lesvi, Sl Pharmaceutical formulations of prasugrel and processes for the preparation thereof
EA039449B1 (ru) 2017-03-27 2022-01-28 Фрути Холдингс Лимитед Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
CN111714458A (zh) * 2019-03-18 2020-09-29 上海复星星泰医药科技有限公司 盐酸普拉格雷的缓释颗粒、含其的制剂及其制备方法
EP4076501A4 (en) 2019-12-16 2024-05-08 Rutgers, the State University of New Jersey CONTINUOUS PROCESSES FOR MANUFACTURING IMPREGNATED POROUS SUPPORTS AND FOR MANUFACTURING IMPREGNATED POROUS SUPPORTS CONTAINING PHARMACEUTICAL PRODUCTS
EP4121028A4 (en) * 2020-03-17 2023-12-13 Rutgers, the State University of New Jersey CONTINUOUS MEL COATING OF PHARMACEUTICAL ACTIVE INGREDIENTS WITH SURFACTANTS TO IMPROVE DISSOLUTION
JP7584249B2 (ja) * 2020-07-27 2024-11-15 東和薬品株式会社 プラスグレルを含む混合物の混合方法及びその利用
US20260048019A1 (en) * 2022-08-12 2026-02-19 Hoffmann-La Roche Inc. Use of co-processed excipients in continuous manufacturing of solid dosage forms

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US20030013740A1 (en) 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
CA2379887C (en) 2002-04-09 2004-01-20 Bernard Charles Sherman Stable tablets comprising simvastatin
US20060217351A1 (en) * 2003-05-05 2006-09-28 Brandt John T Method for treating cardiovascular diseases
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
JP2008540546A (ja) 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20080214599A1 (en) 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
CN101460150B (zh) 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
JPWO2008069262A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
MX2009006037A (es) 2006-12-07 2009-06-16 Lilly Co Eli Un articulo de manufactura para prasugrel.
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
US20100261908A1 (en) 2007-11-09 2010-10-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel , and its salts and polymorphs
WO2009087410A2 (en) 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
ATE482961T1 (de) 2008-04-25 2010-10-15 Sandoz Ag Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
US20090281136A1 (en) 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
PL2398468T3 (pl) 2009-02-17 2017-06-30 Krka, D.D., Novo Mesto Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania
EP2451816A4 (en) 2009-07-06 2013-02-27 Glenmark Generics Ltd CRYSTALLINE FORM OF PRASUGREL HYDROBROMIDE AND PROCESS FOR PREPARING THE SAME

Also Published As

Publication number Publication date
WO2010094471A1 (en) 2010-08-26
EA024980B1 (ru) 2016-11-30
EA201190145A1 (ru) 2012-02-28
EP2398468B1 (en) 2016-11-30
SI2398468T1 (sl) 2017-03-31
EP2398468A1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
SI2398468T1 (sl) Farmacevtske sestave, ki obsegajo prasugrel ali njegove farmacevtsko sprejemljive kislinske adicijske soli in postopek za njihovo pripravo
EP2564847A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVING PRASUGREL SOLUBILITY AND PREPARATION METHOD THEREOF
IL209258A (en) Derivatives of Pyrolopyridine, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses
IL213993A (en) History of 4,3,2,1-tetrahydropyrido [3,2-b] pyrazine-2-one and pharmaceutical preparations containing them
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
IL212734A0 (en) Pharmaceutical compositions comprising imidazoquinolin (amines) and derivatives thereof suitable for local administration
IL217912A (en) History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It
PL2515941T3 (pl) Preparat farmaceutyczny zawierający bewacyzumab
IL219750A (en) Triazulophyridines, a method of preparing them, pharmaceutical preparations containing them and their use in the treatment or prevention of disease
IL220544A (en) History of n - (h1 - indazole - 4 - ram) imidazo [2,1 - a] pyridine - 3 - carboxamide, processes for their preparation and pharmaceutical preparations containing them
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
EP2419138A4 (en) GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS
ZA201200719B (en) Pharmaceutical formulation
ZA201300241B (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
ZA201108384B (en) Aqueous pharmaceutical compositions containing borate-polyol complex
PL2364084T3 (pl) Niskodawkowe kompozycje farmaceutyczne kwasu liponowego i sposoby
IL218539A (en) Annotated 4,1-Androsteadian-3-Oxo-9,6-Dihlo-16-Isoxazolidine-17-Noble N-Converted
IL214420A0 (en) Pharmaceutical compositions comprising tamsulosin and solifenacin for oral administration
PT3029039T (pt) Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
PL2427417T3 (pl) Sole kwasu 3-pentylofenylooctowego i ich farmaceutyczne zastosowania
IL217293A (en) Annotations of 9,8,7,6-tetrahydropyrimido {{a-2,1 pyramidine-4-one)
IL214907A (en) Derivatives of benzothiazines, methods for their preparation and medicinal compounds containing them
ZA201203176B (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej